Published in final edited form as:

Mol Carcinog. 2019 September ; 58(9): 1648–1655. doi:10.1002/mc.23049.

Lessons learned from *SMAD4* loss in squamous cell carcinomas

Ariel L. Hernandez¹, Christian D. Young¹, Jing H. Wang^{2,3}, Xiao-Jing Wang^{1,4,*}

¹Department of Pathology, School of Medicine, University of Colorado, Aurora, CO

²Department of Immunology and Microbiology, University of Colorado, Aurora, CO

³Department of Biomedical Research, National Jewish Health, Denver, CO

⁴Veterans Affairs Medical Center, VA Eastern Colorado Health Care System, Aurora, CO

Abstract

SMAD4 is a potent tumor suppressor and the primary mediator of the TGF β signaling pathway. SMAD4 genetic loss is frequent in squamous cell carcinomas (SCCs). Reports of SMAD4 expression in SCCs vary significantly possibly due to inter-tumor heterogeneity or technical reasons. SMAD4 loss is an initiation event for SCCs. In tumor epithelial cells, SMAD4 mutant SCCs commonly present with increased proliferation, decreased apoptosis, and “Brca-like” genomic instability associated with DNA repair defects. SMAD4 loss also plays a role in expansion of cancer stem cells (CSC). Epithelial SMAD4 loss causes overexpression of TGF β which is released into the tumor microenvironment and contributes to SCC progression through pro-inflammatory and immune evasive mechanisms. SMAD4 loss, while not directly targetable, is associated with multiple targetable pathways that require further studies. Altogether, SMAD4 loss is a potential biomarker in SCCs that should be further studied to gain insight for prognosis and therapeutic approaches to potentially guide future clinical trials and improve SCC patient outcomes.

Keywords

SMAD4 loss; prevalence; tumor initiation; tumor progression; SCCs

Introduction

SMAD proteins were discovered as intracellular signaling mediators of the transforming growth factor β (TGF β) superfamily and were named after non-mammalian homologs: *Sma* genes of *Caenorhabditis elegans* and the *Mad* gene in *Drosophila melanogaster*. SMADs are important for homeostasis during embryonic development, immune response, fibrosis, wound healing, genomic stability, and tumor development¹. Extracellular TGF β ligands bind transmembrane receptors activating receptor kinase activity leading to phosphorylation of members of the intracellular receptor-activated SMAD family, SMAD2 and SMAD3 in the case of TGF β stimulation². Phosphorylated SMAD2/3 heterotrimerize with SMAD4 and

*Corresponding Author: Xiao-Jing Wang MD, PhD, University of Colorado School of Medicine, 12800 East 19th Avenue, Mail stop 8104, Aurora, CO 80045, Phone: (303) 724-3001, Fax: (303) 724-4730, xj.wang@ucdenver.edu.

translocate into the nucleus to interact with SMAD binding elements (SBEs) to regulate transcription of TGF β dependent genes (Figure 1a)². While the primary focus of this review is on SMAD4 as a mediator of TGF β signaling pathways, it is important to note bone morphogenic protein (BMP) and activin signaling pathways are also dependent on SMAD4². Furthermore, TGF β /BMP ligands can also signal through non-canonical pathways including ERK, p38/JNK, Rho/Rac, and PI3K/AKT dependent or independent of SMADs³.

The role of SMAD4 as a tumor suppressor was initially identified in pancreatic cancers as Deleted in Pancreatic Cancer 4 (DPC4)⁴, and SMAD4 loss has since been identified as a key driver in skin cancers and head and neck cancers as well as other cancers⁵⁻⁷. TGF β signaling inhibits epithelial cell growth and promotes cellular differentiation, thus defects in TGF β signaling *via* TGF β RI, TGF β RII, and/or SMAD4 dysregulation promote tumor growth⁸. Impaired TGF β signaling in epithelial cells causes additional TGF β ligand release into the tumor microenvironment (Figure 1b) that stimulates angiogenesis and inflammation in stromal cells with intact TGF β signaling (Figure 1a) that can then promotes tumor growth and progression⁹. This review will discuss the important roles of SMAD4 loss and the associated mechanisms that contribute to tumor initiation and progression of squamous cell carcinomas.

Prevalence of *SMAD4* loss in squamous cell carcinomas (SCCs)

The *SMAD4* gene is located at chromosome 18q¹⁰ and large chromosomal deletion of 18q and loss of one or two *SMAD4* alleles is the most common reason for SMAD4 loss of function in SCCs. Overall, 56% of primary head and neck squamous cell carcinomas (HNSCCs) have SMAD4 genomic alterations^{11,12}. *SMAD4* loss occurs in 35 - 68% of human HNSCCs¹³⁻¹⁵ and occurs in up to 70% of skin SCCs¹⁶; however, *SMAD4* point mutations are rare (< 5%) in these types of SCCs¹⁷. Higher rates of genomic loss (56%) compared to point mutations (< 5%) are consistent with rates of genetic abnormalities in human cancers¹⁸. In contrast, *SMAD4* point mutations are more common in pancreatic cancers (~35%^{19,20}) and colon cancers (~12%²¹) than SCCs.

Reduced SMAD4 protein staining is associated with aggressive SCC tumor progression^{14,15,22}. However, reports of reduced SMAD4 expression vary widely at 12 – 86%^{6,23}. This wide range of reported SMAD4 reduction may be explained by the criteria used to define “reduced SMAD4 expression” and the tissue samples used as SMAD4 positive controls such as adjacent non-malignant tissue versus unrelated normal tissue. For example, reduced *SMAD4* expression, defined as > 50% reduction of mRNA expression per specimen, was observed in 86% of human HNSCCs compared to 67% of the non-malignant adjacent mucosal specimens⁶. By this criteria, “SMAD4 loss” would be under-reported in studies that compared SCCs to non-malignant adjacent mucosal tissue where SMAD4 reduction may also have occurred. Furthermore, multiple reports support that single copy loss of *SMAD4* occurs in 30 – 50% of HNSCCs^{6,10,12,13,24}; however, other reports suggest reduced SMAD4 immunostaining in < 30% of HNSCC cases which maybe be due to control tissues or poor antibody specificity. Additionally, intra-tumor heterogeneity of genomic *SMAD4* loss as well as aneuploidy of chromosome 18 may also contribute to variations in reported *SMAD4* loss¹³. While genomic loss of *SMAD4* is evident in ~ 50%

of SCCs, its detection by immunostaining or RNA expression analyses are not standardized and ideal expression standards for SMAD4 are lacking. With a central role in tumor development and potential therapeutic response marker as discussed below, a standard for “SMAD4 loss” is a critical and logical need in future studies.

SMAD4 loss initiates SCCs

We have shown that SMAD4 downregulation occurs in preneoplastic oral mucosa and actinic keratosis (AKs), suggesting SMAD4 downregulation is an early event in human SCC development^{6, 25}. In genetically engineered mouse models, keratinocyte-specific Smad4 deletion in the oral cavity or skin spontaneously induces SCCs^{5, 6, 25, 26} demonstrating that SMAD4 loss, as a single event, can initiate SCCs. Therefore early stage keratinocyte SMAD4 loss in patients may have a significant impact on SCC initiation in patients. This is quite different from pancreatic and colon cancers where SMAD4 loss occurs at later stages of cancer development and is more associated with metastatic progression^{27–29}. Interestingly, single copy deletion of Smad4 did not initiate HNSCC formation, but it accelerated HNSCC development initiated by oncogenic Kras^{G12D}⁶, which suggests that Smad4 haploid insufficiency can promote oncogene-driven HNSCC development. Keratinocytes-specific Smad4 deletion caused interruption of hair follicle cycling, hyperproliferative hair follicles, progressive hair loss, and well-differentiated skin SCCs^{5, 26}. SCCs with SMAD4 loss activate survival factors including increased AKT, cyclin D1, and c-myc expression and promotes growth of Smad4^{-/-} skin stem cells to promote development of sebaceous adenomas and basal cell carcinomas as well as other cancer types^{5, 26}. Smad4 deletion in mammary epithelial cells of mice also caused mammary tumors with transdifferentiation to squamous histology³⁰. Furthermore, Smad4 deletion promotes PTEN^{-/-} skin tumor formation⁵. Collectively, these reports demonstrate that Smad4 loss promotes SCC initiation and accelerates oncogene-driven SCC development. Thus, early loss of Smad4 appears uniquely pathogenic in SCCs, further emphasizing the need for SMAD4 detection and evaluation in human SCCs.

Survival and invasive mechanisms of SMAD4 mutant SCCs

Several reports have shown that TGFβ/SMAD4 signaling induces growth arrest and/or apoptosis in normal keratinocytes^{1, 6, 31}. TGFβ-induced growth arrest requires SMAD-2, -3, and -4³². Spontaneous HNSCCs development driven by Smad4 deletion was associated with increased proliferation in the Smad4^{-/-} malignant and adjacent-premalignant mucosa compared to Smad4^{+/+} normal mucosa⁶. Inversely, apoptotic cells were less common in Smad4^{-/-} malignant and adjacent-premalignant mucosa compared to normal mucosa⁶. Therefore, Smad4 loss allows for epithelial derived SCCs to escape TGFβ-mediated growth inhibition and survive into tumor development. Mechanistically, Smad4 loss is associated with inactivation of tumor suppressors PTEN and p21 to bypass cell cycle arrest and promote cell proliferation and survival in SCCs²⁶. Furthermore, Smad4 mutant mouse models developed hyperplasia and hyperproliferative hair follicles associated with upregulated c-Myc and cyclin D1 to promote proliferation and downregulated p27 to promote survival⁵. Taken together, SMAD4 loss leads to increased proliferation and

decreased apoptosis to promote tumor development of SCCs; however, additional survival mechanisms are at play.

Cancer stem cells (CSCs) with Smad4 deletion also contribute to tumor development and progression. Mouse models with keratinocyte-specific Smad4 deletion developed tumors in 6-8 months^{5, 26}, but when Smad4 was deleted from K15 positive (K15.Smad4^{-/-}) bulge stem cells, spontaneous skin tumors required 1 year to form³³. The slowed tumor development was likely due to the quiescent nature of bulge stem cells, suggesting that Smad4^{-/-} driven tumor development requires more rapid proliferation. When oncogenic Kras^{G12D} was co-expressed in K15.Smad4^{-/-} bulge stem cells (K15.Kras^{G12D}.Smad4^{-/-}) tumor latency was accelerated to 1 month³³. However, tumor development required Smad4 deletion as mice solely expressing the K15.Kras^{G12D} mutation only developed benign papillomas³³. In contrast, K15.Kras^{G12D}.Smad4^{-/-} bulge stem cells led to the development of multi-lineage skin tumors (SCCs, basal cell carcinomas, trichoepitheliomas, and sebaceous adenomas) likely from uncommitted multipotent stem cells or immediate progenitor cells³³.

Smad4 deletion in stem cells also contributed to the metastatic progression of SCCs. Serial passage of K15.Kras^{G12D}.Smad4^{-/-} tumors presented with more aggressive outgrowth and epithelial-mesenchymal transition (EMT)-mediated metastatic progression which correlated with increased side population (SP) cells, a metastasis-associated CSC population³³. Expansion of metastatic CSCs was associated with miR-9 overexpression³³, and increased miR-9 correlated with a loss of E-cadherin and α -catenin, previously reported potential miR-9 targets associated with EMT and metastasis^{34, 35}. In human SCC metastases, the loss of α -catenin and E-cadherin was more commonly observed in miR-9 positive tumors than in miR-9 negative tumors³³, which suggest that miR-9 is an important driver of metastasis. These Smad4 loss-associated mechanistic findings are consistent with reports that EMT promotes an increase in CSCs and metastasis in other cancer types^{36, 37}.

While it has been well documented that Smad4 is required for TGF β -induced EMT to promote metastasis^{29, 38}, EMT is not always required for metastasis. Early stage EMT is not observed in Smad4^{-/-} SCCs¹⁶ that retain the ability to metastasize^{6, 33}. However, one report suggest that Smad4 downregulation is important for EMT induction by HNSCC cell lines that are already resistant to cetuximab, an EGFR inhibitor³⁹. One may speculate that these cetuximab-resistant, Smad4-deficient HNSCC cell lines unlocked EMT induction through non-TGF β -dependent mechanisms. In addition to EMT, SCCs with Smad4 deficiency may metastasize through other mechanisms induced by pro-inflammatory cytokines and angiogenic response within the tumor-associated stroma⁶. Together, these findings suggest further studies are required to understand how SMAD4 deficient SCCs survive and metastasize through non-EMT pathways such as increased pro-tumorigenic inflammation.

“Brca-like” genomic instability in SMAD4 mutant SCCs

Deletion of Smad4 in the mouse oral epithelia caused spontaneous HNSCC formation associated with increased genomic instability⁶. In particular, Smad4 deletion down-

regulated Fanc/Brca (Fanconi anemia and breast cancer associated) family genes that maintain DNA integrity and are therefore necessary for sustained genomic stability⁶. Fanc family genes were functionally identified as germline mutations in Fanconi anemia (FA) patients who typically died at a young age without bone marrow transplantation due to chromosome instability-associated bone marrow failure⁴⁰. FA patients that survive to adulthood have an HNSCC-risk 500-fold greater than the general population⁴¹. Furthermore, *BRCA1* and *BRCA2* mutations increase genomic instability and are associated with the development of breast and ovarian cancers^{42–44}. Therefore, early SMAD4 loss associated-downregulation of FANC/BRCA expression and the associated genomic instability may lead to the accumulation of genetic defects required to initiate HNSCC development.

We have shown that pre-malignant Smad4^{-/-} oral epithelium with downregulation of Fanc/Brca genes occurred prior to the development of malignancy in mouse models⁶. Similar to FA cells in which DNA crosslinking agents, such as mitomycin C, induces chromosomal breaks and radial structures (Figure 2a)⁴⁵, Smad4^{-/-} keratinocytes exhibit the same characteristics (Figure 2b)⁶. Along with cancer progression, Smad4^{-/-} SCCs had increased genomic instability as demonstrated by abnormal centrosome number and genomic aberrations⁶. SMAD4 restoration in SMAD4 deficient human HNSCC cell lines increased Brca1 and Rad51 expression as well as increased Brca1 and Rad51 DNA repair foci found in the nucleus of cells treated with mitomycin C⁶. Conversely, reduced SMAD4 immunostaining correlated with reduced immunostaining of BRCA1 and RAD51 in human HNSCCs and the adjacent mucosal. Taken together, these data suggest that reduced SMAD4 leads to downregulation of BRCA1 and RAD51 in human HNSCCs⁶. This SMAD4 loss associated-reduction of Brca1 and Rad51 as well as the FA phenotype causes “Brca-like” phenotype, defined as reduced expression or loss of other DNA repair genes-associated functional defect of homologous recombination rather than BRCA mutations *per se*, in SMAD4 deficient SCCs⁴⁶. While single gene deletions of the Fanc/Brca family do not develop HNSCCs⁴⁷, Smad4 loss in keratinocytes disrupts multiple functionally redundant Fanc/Brca family genes to initiate self-perpetuating DNA damage leading to genomic instability and HNSCC development. This is rather unique to keratinocytes, as Smad4 deletion does not predict genomic instability in pancreatic cancers⁴⁸, nor do FA patients have increased incidence to colon or pancreatic cancers⁴⁰.

Skin SCC mouse models driven by Smad4 loss was found to increase susceptibility to ultraviolet (UV)-induced carcinogenesis and subsequent genomic instability²⁵. Smad4 deletion in epidermal keratinocytes accelerated UV-induced skin SCCs²⁵. Multiple DNA repair genes were down regulated by UV-radiated Smad4-null tumors, most notably reduced was Ercc1²⁵. Ercc1 is an essential protein for DNA repair of nucleotide mismatches, double-strand breaks, and crosslinks⁴⁹. Furthermore, most human skin SCCs cases reported co-expressed (86%) or co-repressed (60%) SMAD4 and ERCC1²⁵. However, Ercc1 is not a direct target of Smad4⁵⁰, but instead Ercc1 was shown to be directly regulated by Snail²⁵. Snail is a direct target of Smad4^{16,51} that was also down regulated in the UV-radiated Smad4-null specimens²⁵. This suggests that Smad4 protects keratinocytes from UV-induced DNA damage by upregulating Snail-dependent Ercc1 to maintain functional DNA repair. Similar expression patterns of SNAIL and ERCC1 have been reported in HNSCCs and

bladder cancer^{52, 53}, therefore, SNAIL-regulated ERCC1 expression may occur broadly in human cancers. Future studies are necessary to identify the stage-specific effects of Smad4, Snail, and Ercc1-associated DNA repair in SCC initiation and progression. Additionally, Smad4 loss was associated with reduced expression of other DNA repair pathway genes (Exo1, Chaf1a, and Mre11²⁵) although it remains unknown how reduced expression of these genes affects UV-induced SCC development. Thus, SMAD4 regulates multiple nodes of DNA damage response and loss of SMAD4 causes genomic instability to promote SCC progression, placing SMAD4 as a central mediator of genomic stability.

Tumor microenvironment and progression of SMAD4 deficient SCCs

Loss of SMAD4 led to spontaneous SCC development associated with increased inflammatory infiltration of the tumor microenvironment⁶ likely exasperated by neoantigens associated with genomic instability. TGFβ1 ligand expression is increased in the tumor epithelial cells of Smad4^{-/-} SCCs, and TGFβ1 overexpression was associated with increased infiltration of neutrophils, T cells, and Th17 cells in the tumor microenvironment⁶. Smad4 loss-associated inflammation was abrogated in a Smad3^{+/-} background, suggesting that inflammation in the microenvironment of Smad4^{-/-} SCCs requires Smad3-dependent TGFβ signaling⁶. Smad4^{-/-} SCCs show elevated cytokines including the chemoattractant proteins MCP-1, MCP-2, and MIP-2, compared Smad4^{+/+} mucosa⁶. These cytokines have also been shown to be upregulated in skin keratinocytes with overexpressed TGFβ1⁵⁴. It is well known that tumor cells can influence the local immune response within the tumor microenvironment⁵⁵ by producing inflammatory or immunosuppressive cytokines, recruiting immune suppressive cells, restraining T cell response via modulating the expression of checkpoint pathway components, and reprogramming T regulatory cells (Tregs) to be more suppressive⁵⁶⁻⁵⁹. Therefore, SMAD4 deficient SCCs induce a pro-tumorigenic immune response to promote SCC development.

SMAD4 loss may also be necessary for tumor evasion of the immune system and subsequent progression of SCCs. K15.Kras^{G12D}.Smad4^{-/-} SCC cells are metastatic in mouse models³³. K15.Kras^{G12D}.Smad4^{-/-} SCC tumor transplants develop secondary lesions, despite infiltration of active CD8⁺ T cell into the primary tumor microenvironment⁶⁰. However, K15.Kras^{G12D}.Smad4^{-/-} SCC primary tumor growth was unaffected by the presence of CD8⁺ cells, suggesting that immune evasion or T cell exhaustion. Several immune checkpoints have been implicated in preventing cytotoxic T cell killing of tumor cells including programmed cell death 1 (PD-1), PD-ligand 1 (PD-L1)⁶¹ and lymphocyte activation gene-3 (LAG-3)⁶². The K15.Kras^{G12D}.Smad4^{-/-} SCC tumors were infiltrated by active CD8⁺ T cells that were PD-1⁺ and LAG-3⁺ to indicate immune evasion by the tumors⁶⁰. Furthermore, a large percent of the CD8⁺ T cells downregulated T cell antigen receptor (TCR) β chain, an indication of suppressed CD8⁺ T cells⁶⁰. Isolated K15.Kras^{G12D}.Smad4^{-/-} SCC tumor cells also expressed higher PD-L1 in response to infiltrating CD8⁺ T cells, and K15.Kras^{G12D}.Smad4^{-/-} SCC tumor cells isolated from CD8-null mice had reduced PD-L1 expression⁶⁰ to further support an immune-evasion phenotype by these Smad4-null tumors. Therefore, SMAD4 loss may predict evasion of active T cells by PD-1/PD-L1 and LAG3 in SCCs, but testing of this hypothesis in other models is necessary.

Potential therapeutic approaches against Smad4 deficient SCCs

SMAD4 status may function as a biomarker for drug selection in SCCs as *BRCA* mutations have in breast and ovarian cancers. For example, *BRCA* mutant breast and ovarian cancer patients are being treated with the FDA approved PARP inhibitor, olaparib, which causes synthetic lethality due to the defective DNA damage repair mechanisms and increased genomic instability inherent with *BRCA* mutation and exacerbated by DNA damage repair inhibition^{63, 64}. SMAD4 deficient SCCs present a *BRCA*-like phenotype with decreased Fanc/Brca expression and increased sensitivity to genotoxic agents⁶. Phase I clinical trials have reported olaparib with standard care (cetuximab and radiation) was well tolerated by patients with advanced head and neck cancer⁶⁵. Therefore, it is worthwhile to assess if SMAD4 deficient SCCs are more sensitive to PARP inhibition. Additionally, numerous DNA repair inhibitors or modulators are being studied as anti-cancer agents⁶⁶, such as DNA topoisomerase inhibitors, which suppressed Smad4 deficient lung cancers^{67, 68}. Clinical data from SCC patients treated with these drugs could also reveal if SMAD4 status predicts their therapeutic responses.

The increased TGFβ-mediated signaling in the tumor microenvironment of SMAD4 mutant SCCs^{6, 69} suggests therapeutic strategies inhibiting stromal TGFβ. Alternatively, immunotherapies may be effective against SMAD4 deficient SCCs as there are several checkpoint inhibitors FDA approved that target PD-1 or PD-L1. For instance, K15.Kras^{G12D}.Smad4^{-/-} SCC tumor growth was suppressed by dual-blockade of immune checkpoint inhibitors, anti-PD-1 and anti-LAG3⁶⁰. Immunotherapies also have the potential to prime the host immune system to recognize tumor neoantigens associated with genomic instability and help prevent future tumor reoccurrence. Because single therapeutic approaches are often met with resistance, it is more likely that a combination targeting multiple SMAD4 deficient-associated mechanisms in addition to standard care approaches, such as olaparib with PD-1/PD-L1 blockade and radiation, would be more effective at reducing SMAD4 deficient SCC tumor burden.

Summary and future perspectives

Here, we review the unique functional impacts of SMAD4 loss in SCCs through its direct effects on stratified epithelial cells and indirect effects on stromal microenvironment (Figure 3), and suggest various targetable mechanisms important for tumor initiation and progression of SMAD4 deficient SCCs. Therefore, rational clinical trials that include measurement of SMAD4 loss as a relevant biomarker of response will be required to determine which biological observations are relevant for therapeutic approaches against human SCCs.

Acknowledgements

We apologize for not being able to cite all related publications. ALH is supported by Continuing Umbrella of Research Experiences (CURE) Supplement to the National Research Service Award Institutional Training Grant (T32CA174648). XJW is supported by VA merit award (I01 BX003232) and by NIH R01 (DE024371). Ongoing related work from labs of JHW and XJW are also supported by NIH R01s DE027329 and DE028420.

Abbreviations:

SCCs	squamous cell carcinomas
LOH	Loss of heterozygosity
CSC	cancer stem cells
SBEs	SMAD binding elements
EMT	epithelial-mesenchymal transition
FA	Fanconi anemia

References

1. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell*. 2003;113: 685–700. [PubMed: 12809600]
2. Massague J, Seoane J, Wotton D. Smad transcription factors. *Genes Dev*. 2005;19: 2783–2810. [PubMed: 16322555]
3. Zhang YE. Non-Smad pathways in TGF-beta signaling. *Cell Res*. 2009;19: 128–139. [PubMed: 19114990]
4. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science*. 1996;271: 350–353. [PubMed: 8553070]
5. Yang L, Mao C, Teng Y, et al. Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. *Cancer Res*. 2005;65: 8671–8678. [PubMed: 16204035]
6. Bornstein S, White R, Malkoski S, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. *J Clin Invest*. 2009;119: 3408–3419. [PubMed: 19841536]
7. Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. *Int J Biol Sci*. 2018;14: 111–123. [PubMed: 29483830]
8. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. *Cytokine Growth Factor Rev*. 2006;17: 41–58. [PubMed: 16310402]
9. Blobel GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. *N Engl J Med*. 2000;342: 1350–1358. [PubMed: 10793168]
10. Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L. Presence of multiple contiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. *Clin Cancer Res*. 1998;4: 539–544. [PubMed: 9533520]
11. Takebayashi S, Hickson A, Ogawa T, et al. Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. *Genes Chromosomes Cancer*. 2004;41: 145–154. [PubMed: 15287027]
12. Takebayashi S, Ogawa T, Jung KY, et al. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. *Cancer Res*. 2000;60: 3397–3403. [PubMed: 10910046]
13. Hernandez AL, Wang Y, Somerset HL, et al. Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas. *Mol Carcinog*. 2018.
14. Wang X, Sun W, Bai J, et al. Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma. *Mol Biol Rep*. 2009;36: 861–869. [PubMed: 18418730]
15. Natsugoe S, Xiangming C, Matsumoto M, et al. Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. *Clin Cancer Res*. 2002;8: 1838–1842. [PubMed: 12060625]
16. Hoot KE, Lighthall J, Han G, et al. Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. *J Clin Invest*. 2008;118: 2722–2732. [PubMed: 18618014]

17. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science*. 2011;333: 1154–1157. [PubMed: 21798897]
18. Mendelsohn J. The molecular basis of cancer. Philadelphia, PA: Saunders/Elsevier, 2008:xix, 757 p.
19. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res*. 1997;57: 1731–1734. [PubMed: 9135016]
20. Yatsuoka T, Sunamura M, Furukawa T, et al. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. *Am J Gastroenterol*. 2000;95: 2080–2085. [PubMed: 10950061]
21. Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. *Oncogene*. 1999;18: 3098–3103. [PubMed: 10340381]
22. Fukuchi M, Masuda N, Miyazaki T, et al. Decreased Smad4 expression in the transforming growth factor-beta signaling pathway during progression of esophageal squamous cell carcinoma. *Cancer*. 2002;95: 737–743. [PubMed: 12209716]
23. Malkoski SP, Wang XJ. Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. *FEBS Lett*. 2012;586: 1984–1992. [PubMed: 22321641]
24. Kim SK, Fan Y, Papadimitrakopoulou V, et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. *Cancer Res*. 1996;56: 2519–2521. [PubMed: 8653689]
25. Mitra D, Fernandez P, Bian L, et al. Smad4 loss in mouse keratinocytes leads to increased susceptibility to UV carcinogenesis with reduced Ercc1-mediated DNA repair. *J Invest Dermatol*. 2013;133: 2609–2616. [PubMed: 23648546]
26. Qiao W, Li AG, Owens P, Xu X, Wang XJ, Deng CX. Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. *Oncogene*. 2006;25: 207–217. [PubMed: 16170355]
27. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. *Cancer Res*. 2000;60: 2002–2006. [PubMed: 10766191]
28. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *J Clin Oncol*. 2009;27: 1806–1813. [PubMed: 19273710]
29. Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. *Genes Dev*. 2006;20: 3130–3146. [PubMed: 17114584]
30. Li W, Qiao W, Chen L, et al. Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. *Development*. 2003;130: 6143–6153. [PubMed: 14597578]
31. Ten Dijke P, Goumans MJ, Itoh F, Itoh S. Regulation of cell proliferation by Smad proteins. *J Cell Physiol*. 2002;191: 1–16. [PubMed: 11920677]
32. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. *Nat Rev Cancer*. 2003;3: 807–821. [PubMed: 14557817]
33. White RA, Neiman JM, Reddi A, et al. Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. *J Clin Invest*. 2013;123: 4390–4404. [PubMed: 23999427]
34. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. *Nat Cell Biol*. 2010;12: 247–256. [PubMed: 20173740]
35. Zhu L, Chen H, Zhou D, et al. MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. *Med Oncol*. 2012;29: 1037–1043. [PubMed: 21562850]
36. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*. 2008;133: 704–715. [PubMed: 18485877]
37. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature*. 2007;449: 682–688. [PubMed: 17898713]
38. David CJ, Huang YH, Chen M, et al. TGF-beta Tumor Suppression through a Lethal EMT. *Cell*. 2016;164: 1015–1030. [PubMed: 26898331]

39. Cheng H, Fertig EJ, Ozawa H, et al. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. *Cancer Biol Ther.* 2015;16: 1252–1258. [PubMed: 26046389]
40. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. *N Engl J Med.* 2010;362: 1909–1919. [PubMed: 20484397]
41. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. *Arch Otolaryngol Head Neck Surg.* 2003;129: 106–112. [PubMed: 12525204]
42. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. *Nucleic Acids Res.* 2006;34: 1416–1426. [PubMed: 16522651]
43. Deng CX, Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. *Oncogene.* 2000;19: 1059–1064. [PubMed: 10713690]
44. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. *Science.* 1994;266: 120–122. [PubMed: 7939630]
45. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)linked to DNA repair. *Cell.* 2005;123: 1191–1198. [PubMed: 16377561]
46. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. *Cell Cycle.* 2014;10: 1192–1199.
47. Houghtaling S, Timmers C, Noll M, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. *Genes Dev.* 2003;17: 2021–2035. [PubMed: 12893777]
48. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. *Cancer Cell.* 2007;11: 229–243. [PubMed: 17349581]
49. Friboulet L, Postel-Vinay S, Sourisseau T, et al. ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. *Cell Cycle.* 2013;12: 3298–3306. [PubMed: 24036546]
50. Koinuma D, Tsutsumi S, Kamimura N, Imamura T, Aburatani H, Miyazono K. Promoter-wide analysis of Smad4 binding sites in human epithelial cells. *Cancer Sci.* 2009;100: 2133–2142. [PubMed: 19686287]
51. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. *J Biol Chem.* 2003;278: 21113–21123. [PubMed: 12665527]
52. Hsu DS, Lan HY, Huang CH, et al. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. *Clin Cancer Res.* 2010;16: 4561–4571. [PubMed: 20823140]
53. Kawashima A, Takayama H, Kawamura N, et al. Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. *Oncol Lett.* 2012;4: 15–21. [PubMed: 22807952]
54. Li AG, Wang D, Feng XH, Wang XJ. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. *EMBO J.* 2004;23: 1770–1781. [PubMed: 15057277]
55. Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. *Cancers (Basel).* 2015;7: 2397–2414. [PubMed: 26690220]
56. Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. *Br J Cancer.* 2013;109: 2629–2635. [PubMed: 24169351]
57. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. *Br J Cancer.* 2005;92: 913–920. [PubMed: 15714205]
58. De Costa AM, Schuyler CA, Walker DD, Young MR. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck. *Cancer Immunol Immunother.* 2012;61: 927–939. [PubMed: 22116344]

59. Lau KM, Cheng SH, Lo KW, et al. Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. *Br J Cancer*. 2007;96: 617–622. [PubMed: 17262084]
60. Mishra AK, Kadoishi T, Wang X, et al. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. *Oncotarget*. 2016;7: 81341–81356. [PubMed: 27835902]
61. Spranger S, Spaepen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. *Sci Transl Med*. 2013;5: 200ra116.
62. Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. *Eur J Immunol*. 2003;33: 970–979. [PubMed: 12672063]
63. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*. 2005;434: 917–921. [PubMed: 15829967]
64. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*. 2009;361: 123–134. [PubMed: 19553641]
65. Karam SD, Reddy K, Blatchford PJ, et al. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. *Clin Cancer Res*. 2018;24: 4949–4959. [PubMed: 30084837]
66. Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. *Cancer Discov*. 2017;7: 20–37. [PubMed: 28003236]
67. Haeger SM, Thompson JJ, Kalra S, et al. Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. *Oncogene*. 2016;35: 577–586. [PubMed: 25893305]
68. Ziemke M, Patil T, Nolan K, Tippimanchai D, Malkoski SP. Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. *Lung Cancer*. 2017;109: 28–35. [PubMed: 28577946]
69. Owens P, Engelking E, Han G, Haeger SM, Wang XJ. Epidermal Smad4 deletion results in aberrant wound healing. *Am J Pathol*. 2010;176: 122–133. [PubMed: 19959815]

Figure 1. Normal versus deficient SMAD4 signaling.

(a) SMAD4 dependent TGFβ signaling in normal epithelial and stromal cells. (b) SMAD4 loss results in increased TGFβ production and release TGFβ into the extracellular matrix that acts on stromal cells, inducing a pro-tumorigenic microenvironment.

Figure 2. “Brca-like” phenotype in SMAD4 deficient keratinocytes.

(a) DNA repair and replication in normal, DNA damaged, and Fanconi anemia cells. (b) Karyotype of SMAD4 null keratinocytes treated with mitomycin C (40 ng/mL) leads to chromatin with radial structures (red circles) and chromosome breaks (red arrows), hallmarks observed in Fanconi anemia patients.

Figure 3. SMAD4 deficient SCC initiation and progression.

Loss of SMAD4 causes increased genomic instability to initiate SCC formation and progression. A pro-tumorigenic microenvironment is induced by TGFβ-associated inflammation and immune suppression to promote tumor growth and metastatic progression.